EP3302450A4 - METHODS OF AMINE PEGYLATION FOR THE PREPARATION OF SPECIFIC PROTEIN CONJUGATES OF A SITE - Google Patents

METHODS OF AMINE PEGYLATION FOR THE PREPARATION OF SPECIFIC PROTEIN CONJUGATES OF A SITE Download PDF

Info

Publication number
EP3302450A4
EP3302450A4 EP16803982.4A EP16803982A EP3302450A4 EP 3302450 A4 EP3302450 A4 EP 3302450A4 EP 16803982 A EP16803982 A EP 16803982A EP 3302450 A4 EP3302450 A4 EP 3302450A4
Authority
EP
European Patent Office
Prior art keywords
site
preparation
methods
specific protein
protein conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16803982.4A
Other languages
German (de)
French (fr)
Other versions
EP3302450A1 (en
Inventor
Mary S. Rosendahl
Sankaram B. Mantripragada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rezolute Inc
Original Assignee
Antriabio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antriabio Inc filed Critical Antriabio Inc
Publication of EP3302450A1 publication Critical patent/EP3302450A1/en
Publication of EP3302450A4 publication Critical patent/EP3302450A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP16803982.4A 2015-06-04 2016-05-19 METHODS OF AMINE PEGYLATION FOR THE PREPARATION OF SPECIFIC PROTEIN CONJUGATES OF A SITE Withdrawn EP3302450A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170933P 2015-06-04 2015-06-04
PCT/US2016/033190 WO2016196017A1 (en) 2015-06-04 2016-05-19 Amine pegylation methods for the preparation of site-specific protein conjugates

Publications (2)

Publication Number Publication Date
EP3302450A1 EP3302450A1 (en) 2018-04-11
EP3302450A4 true EP3302450A4 (en) 2019-01-16

Family

ID=57442063

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16803982.4A Withdrawn EP3302450A4 (en) 2015-06-04 2016-05-19 METHODS OF AMINE PEGYLATION FOR THE PREPARATION OF SPECIFIC PROTEIN CONJUGATES OF A SITE

Country Status (12)

Country Link
US (1) US10220075B2 (en)
EP (1) EP3302450A4 (en)
JP (1) JP2018516874A (en)
KR (1) KR20180015131A (en)
CN (1) CN107708679A (en)
AU (1) AU2016270302B2 (en)
BR (1) BR112017023145A2 (en)
CA (1) CA2981501A1 (en)
MX (1) MX2017014586A (en)
RU (1) RU2730848C2 (en)
WO (1) WO2016196017A1 (en)
ZA (1) ZA201708573B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115029204A (en) * 2022-07-15 2022-09-09 曾会明 Wine with SOD activity and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083006A1 (en) * 2003-04-11 2007-04-12 Pr Pharmaceuticals, Inc. Method for preparation of site-specific protein conjugates
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
AU2003236096A1 (en) 2002-04-11 2003-10-20 Mochida Pharmaceutical Co., Ltd. Peptide chemically modified with polyethylene glycol
JP2006501820A (en) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン Modified GLP-1 receptor agonists and their pharmacological uses
DE60313786T2 (en) 2002-09-27 2008-01-24 F. Hoffmann-La Roche Ag POLY (ETHYLENE GLYCOL) CONJUGATES OF INSULINARY GROWTH FACTOR BINDING PROTEIN-4
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
AU2004231461B2 (en) 2003-03-19 2009-11-12 Eli Lilly And Company Polyethelene glycol linked GLP-1 compounds
KR101135244B1 (en) 2007-11-29 2012-04-24 한미사이언스 주식회사 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP1710304A4 (en) 2003-12-24 2008-01-16 Shionogi & Co PROCESS FOR PRODUCING A PROTEIN POLYMER COMPOSITE
JP2008500275A (en) 2003-12-31 2008-01-10 セントカー・インコーポレーテツド Novel recombinant protein having an N-terminal free thiol
KR20060029770A (en) 2004-10-04 2006-04-07 주식회사 펙스피어 Selective PET Bonder of JP-1 and its manufacturing method
CN101166545B (en) 2005-05-13 2011-06-15 伊莱利利公司 Glp-1 pegylated compounds
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
RU2424246C2 (en) 2006-05-26 2011-07-20 Ипсен Фарма С.А.С. Method for site-specific pegylation
JP5550338B2 (en) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス PEGylated insulin
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
JP2008156283A (en) * 2006-12-25 2008-07-10 Kyowa Hakko Kogyo Co Ltd Method for producing water-soluble polymer-modified polypeptide
US20120178914A1 (en) 2009-09-25 2012-07-12 Vybion, Inc. Polypeptide modification
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
WO2012054882A1 (en) 2010-10-21 2012-04-26 Kci Licensing, Inc. Debridement hand tool
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
KR101746686B1 (en) 2010-10-26 2017-06-15 한미사이언스 주식회사 An GLP-2 conjugate using an immunoglobulin fragment
JP6055817B2 (en) * 2011-05-12 2016-12-27 バイオノミックス リミテッド Method for preparing naphthyridine
CN102786590A (en) 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 Branching-type PEG-modified GLP-1 analogs and pharmaceutically acceptable salts thereof
EP2714093A1 (en) 2011-05-27 2014-04-09 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
MX2013015168A (en) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists.
AR090281A1 (en) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
AR094821A1 (en) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
AU2014318579A1 (en) 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
KR102455171B1 (en) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083006A1 (en) * 2003-04-11 2007-04-12 Pr Pharmaceuticals, Inc. Method for preparation of site-specific protein conjugates
US20110171312A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016196017A1 *

Also Published As

Publication number Publication date
KR20180015131A (en) 2018-02-12
ZA201708573B (en) 2019-08-28
RU2730848C2 (en) 2020-08-26
JP2018516874A (en) 2018-06-28
CN107708679A (en) 2018-02-16
WO2016196017A1 (en) 2016-12-08
BR112017023145A2 (en) 2018-07-10
EP3302450A1 (en) 2018-04-11
US10220075B2 (en) 2019-03-05
RU2017145825A3 (en) 2019-11-18
MX2017014586A (en) 2018-03-09
AU2016270302B2 (en) 2020-09-17
AU2016270302A1 (en) 2017-10-19
US20160354478A1 (en) 2016-12-08
RU2017145825A (en) 2019-07-10
CA2981501A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
EP3315512A4 (en) METHOD FOR THE SELECTIVE PREPARATION OF AN ANTIBODY-MEDICINAL CONJUGATE
EP3353278A4 (en) SAMPLE PREPARATION FOR COMPLICATED SAMPLE TYPES
EP2892929A4 (en) METHODS AND COMPOSITIONS FOR THE SPECIFIC MARKING OF A SITE OF PEPTIDES AND PROTEINS
EP3400285A4 (en) METHODS FOR IMPROVING MILK PRODUCTION BY ADMINISTERING MICROBIENT CONSORTIA
EP3484518A4 (en) ANTIBODY ADJUVANT CONJUGATES
MA43242A (en) MIXTURE FOR PROCESSING UREA-BASED FERTILIZERS
EP3707821A4 (en) ANCHORING PLATFORM SET
EP3294341A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING ANTIBODY CONJUGATES
EP3377520A4 (en) METHOD FOR EXTENDING THE HALF-LIFE OF A PROTEIN
EP3504196A4 (en) PROCESSES FOR THE PREPARATION OF OLAPARIB
MA44054A (en) BISPECIFIC ANTIBODY PLATFORM
MA55193A (en) METHODS FOR PREPARING A PI3K INHIBITOR
EP3383418A4 (en) SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
MA45154A (en) OLIGOMER PREPARATION PROCESSES
EP3627918C0 (en) RADIOSEARCH FOR COVERAGE EXTENSION FOR EC-GSM
MA43587A (en) THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES
EP3476871A4 (en) OLEFIN POLYMER AND PREPARATION METHOD THEREOF
EP3397360A4 (en) PEDAL ASSEMBLY FOR EXERCISE MACHINE
EP2970037A4 (en) PROCESSES FOR THE PREPARATION OF ALKYLFURANS
EP3350475A4 (en) BAND JOINER FOR CONVEYOR BASED ON ADVANCED COMPONENT
EP3509339A4 (en) AP INVESTMENT
EP3442657A4 (en) METHOD FOR EVALUATING THERAPEUTIC AGENTS FOR JOINTS
EP3341151A4 (en) CHALUMEAU OXYCOUPING MACHINE
EP3902792A4 (en) METHOD FOR THE PREPARATION OF ANTHRANILAMIDES
EP3345152A4 (en) CONTINUOUS AUCTION PORTAL

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181219

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/60 20170101ALI20181213BHEP

Ipc: A61K 38/28 20060101AFI20181213BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REZOLUTE, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200116

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200918

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210129